133P Phase I/II study of XTX101: A masked, tumor-activated Fc-enhanced anti-CTLA-4, in patients with advanced solid tumors

Saved in:
Bibliographic Details
Published inImmuno-oncology technology Vol. 20; p. 100605
Main Authors Davar, D., Knecht, J.G., Vandross, A.L., Perez, C.A., Miller, D.M., Powderly, J., Bessudo, A., Montazeri, K., Mooradian, M.J., Gupta, A., Patel, E., Fantini, D., Paramasivan, S., Crowe, D., Duncan, M., Uptain, S., Luptakova, K., Sullivan, R.
Format Journal Article
LanguageEnglish
Published Elsevier Ltd 01.12.2023
Online AccessGet full text

Cover

More Information
ISSN:2590-0188
2590-0188
DOI:10.1016/j.iotech.2023.100605